Dirk Brockstedt - RAPT Therapeutics Chief Officer
| RAPT Stock | USD 1.31 0.11 9.17% |
Insider
Dirk Brockstedt is Chief Officer of RAPT Therapeutics
| Age | 56 |
| Phone | 650 489 9000 |
| Web | https://www.rapt.com |
Dirk Brockstedt Latest Insider Activity
Tracking and analyzing the buying and selling activities of Dirk Brockstedt against RAPT Therapeutics stock is an integral part of due diligence when investing in RAPT Therapeutics. Dirk Brockstedt insider activity provides valuable insight into whether RAPT Therapeutics is net buyers or sellers over its current business cycle. Note, RAPT Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell RAPT Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Dirk Brockstedt over three months ago Disposition of 75000 shares by Dirk Brockstedt of RAPT Therapeutics at 24.75 subject to Rule 16b-3 | ||
Dirk Brockstedt over three months ago Disposition of 75000 shares by Dirk Brockstedt of RAPT Therapeutics at 24.75 subject to Rule 16b-3 |
RAPT Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4113) % which means that it has lost $0.4113 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7709) %, meaning that it created substantial loss on money invested by shareholders. RAPT Therapeutics' management efficiency ratios could be used to measure how well RAPT Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Sonia DPHIL | PepGen | 38 | |
| Phil JD | Monte Rosa Therapeutics | 45 | |
| Craig Muir | Pliant Therapeutics | N/A | |
| Eric Easom | AN2 Therapeutics | 57 | |
| Julie CPA | Design Therapeutics | N/A | |
| Noel MBA | PepGen | 55 | |
| Sharon Townson | Monte Rosa Therapeutics | 50 | |
| Michael Gait | PepGen | N/A | |
| Cynthia SeidelDugan | Werewolf Therapeutics | 65 | |
| Jennifer Cormier | PepGen | N/A | |
| John Castle | Monte Rosa Therapeutics | 54 | |
| Dawn Kalmar | Stoke Therapeutics | 47 | |
| Steven Chan | Connect Biopharma Holdings | 52 | |
| Christopher Frankenfield | Xilio Development | 43 | |
| Jochen Knolle | Pharvaris BV | 74 | |
| Bill DeGrado | Pliant Therapeutics | N/A | |
| Malinda Longphre | Connect Biopharma Holdings | N/A | |
| Uli Bialucha | Xilio Development | N/A | |
| Mark Murcko | Relay Therapeutics | 64 | |
| Sean Jeffries | Design Therapeutics | 45 | |
| Stacey Davis | Xilio Development | N/A | |
Management Performance
| Return On Equity | -0.77 | ||||
| Return On Asset | -0.41 |
RAPT Therapeutics Leadership Team
Elected by the shareholders, the RAPT Therapeutics' board of directors comprises two types of representatives: RAPT Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RAPT. The board's role is to monitor RAPT Therapeutics' management team and ensure that shareholders' interests are well served. RAPT Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RAPT Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gwen Carscadden, Chief Officer | ||
| Rodney Young, Principal CFO | ||
| David Wustrow, Senior Development | ||
| William Ho, Chief Officer | ||
| Jennifer Nicholson, Senior Assurance | ||
| Michael Listgarten, General Counsel | ||
| William MD, Chief Officer | ||
| Steve Young, Vice Technology | ||
| Paul Kassner, Senior Biology | ||
| Nipun MBA, Senior Operations | ||
| Brian MD, President CEO | ||
| Dirk Brockstedt, Chief Officer |
RAPT Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is RAPT Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.77 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | (55.61 M) | ||||
| Shares Outstanding | 132.01 M | ||||
| Shares Owned By Insiders | 0.49 % | ||||
| Shares Owned By Institutions | 96.42 % | ||||
| Number Of Shares Shorted | 2.81 M | ||||
| Price To Book | 0.90 X | ||||
| Price To Sales | 411.22 X | ||||
| Gross Profit | 1.53 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for RAPT Stock Analysis
When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.